Previous 10 | Next 10 |
2024-01-30 10:22:11 ET More on Arcus Biosciences Arcus Biosciences: Showing There Might Be Something To TIGIT After All Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript Gilead invest...
2024-01-29 15:17:00 ET Summary Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher, driven by the growth of Xywav, Rylaze, and Epi...
2024-01-26 08:25:42 ET Summary BeiGene has an impressive pipeline and global market penetration, offering significant upside potential. The company's recent pipeline advancements and successful clinical trials have reduced its valuation and made it more attractive. BeiGene's g...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. This press release features multimedia. View the ful...
2024-01-22 08:50:51 ET Summary Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies. Protein degradation platform offers several advantages over other BTK drugs, such as ability to...
2024-01-18 13:25:54 ET Eli Lilly’s ( NYSE: LLY ) new cancer therapy, Jaypirca (pirtobrutinib), is expected to dominate the market for BTK inhibitors for chronic lymphocytic leukemia (CLL) in seven major markets, data and analytics firm GlobalData said Friday. BTK in...
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of BRUKINSA versus IMBRUVICA ® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase (BTK) inhibitor trial to demonstrat...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , 2024 with a presentation at 1:30 pm PT. A live webcast of this event c...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...